Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tykerb in Neoadjuvant HER2+ Breast Cancer
NCT00455039Phase 2Withdrawn
- Sponsor
- The University of New Mexico
- Start
- Jul 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in breast cancer, sponsored by The University of New Mexico. Planned start Jul 2023; status: withdrawn.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00455039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00455039.